Association of Changes in Norepinephrine and Serotonin Transporter Expression with the Long-Term Behavioral Effects of Antidepressant Drugs
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Previous work has shown that repeated desipramine treatment causes downregulation of the norepinephrine transporter (NET) and persistent antidepressant-like effects on behavior, ie effects observed 2 days after discontinuation of drug treatment when acute effects are minimized. The present study examined whether this mechanism generalizes to other antidepressants and also is evident for the serotonin transporter (SERT). Treatment of rats for 14 days with 20 mg/kg per day protriptyline or 7.5 mg/kg per day sertraline reduced NET and SERT expression, respectively, in cerebral cortex and hippocampus; these treatments also induced a persistent antidepressant-like effect on forced-swim behavior. Increased serotonergic neurotransmission likely mediated the behavioral effect of sertraline, as it was blocked by inhibition of serotonin synthesis with p-chlorophenylalanine; a parallel effect was observed previously for desipramine and noradrenergic neurotransmission. Treatment with 20 mg/kg per day reboxetine for 42, but not 14, days reduced NET expression; antidepressant-like effects on behavior were observed for both treatment durations. Treatment for 14 days with 70 mg/kg per day venlafaxine, which inhibits both the NET and SERT, or 10 mg/kg per day phenelzine, a monoamine oxidase inhibitor, produced antidepressant-like effects on behavior without altering NET or SERT expression. For all drugs tested, reductions of NET and SERT protein were not accompanied by reduced NET or SERT mRNA in locus coeruleus or dorsal raphe nucleus, respectively. Overall, the present results suggest an important, though not universal, role for NET and SERT regulation in the long-term behavioral effects of antidepressants. Understanding the mechanisms underlying transporter regulation in vivo may suggest novel targets for the development of antidepressant drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 1×
“On day 1 (ie 1 day after cessation of antidepressant treatment), the rats were pretested for 15 min to develop an immobility posture after initial escape-oriented movements (Cryan et al, 2002).”
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 3×
“…inhibitors (NRIs), and serotonin–norepinephrine reuptake inhibitors (SNRIs), this results from inhibition of the norepinephrine or serotonin transporters (NET, SERT), which clear the transmitters from the synapse (Beyer et al, 2002; Katz et al, 2004; Morilak and Frazer, 2004; White et al, 2005).”
Miller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192 · cited 13×
“Further, it is found that the SERT mRNA expression in the raphe nucleus is unchanged following chronic treatment with SRIs (Benmansour et al, 1999; Abumaria et al, 2007).”
InfluentialWyszynski, M., Kharazia, V., Shanghvi, R., Rao, A., Beggs, A. H., Craig, A. M., Weinberg, R., & Sheng, M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01383.1998 · Cited by 168 · cited 1×
“The supernatant was centrifuged at 20 000g for 30 min to obtain a crude synaptosomal fraction (Lin et al, 1998; Wyszynski et al, 1998; Dunah and Standaert, 2001).”
Delayed pharmacological effects of antidepressants
Frazer, A., & Benmansour, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001015 · Cited by 160 · cited 4×
“Although enhanced monoaminergic neurotransmission appears to be an effect shared by antidepressants from different chemical and pharmacological classes, its relationship to antidepressant efficacy is unclear as therapeutic effects develop gradually over time with repeated treatment (Frazer and Benmansour, 2002; Nelson…”
Influential
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227
Noradrenergic Modulation of Cognition in Health and Disease
Borodovitsyna, O., Flamini, M., & Chandler, D. (2017) · Neural Plasticity · doi:10.1155/2017/6031478 · Cited by 205
“Importantly, there is strong evidence linking dysfunction of the noradrenergic system tomany such conditions, including depression [28, 29], anxiety [30, 31], attention-deficit hyperactivity disorder (ADHD) [32–36], schizophrenia [37–39], autism [40], Parkinson’s disease [29, 41, 42], and Alzheimer’s disease [27, 43,…”
BackgroundNeuron density and serotonin receptor binding in prefrontal cortex in suicide
Underwood, M. D., Kassir, S. A., Bakalian, M. J., Galfalvy, H., Mann, J. J., & Arango, V. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000691 · Cited by 100
Metadata
- Authors
- Zhao, Z., Zhang, H.-T., Bootzin, E., Millan, M. J., & O'Donnell, J. M.
- Venue
- Neuropsychopharmacology
- Published
- 2008-10-15
- Volume
- 34
- Issue
- 6
- Pages
- 1467-1481
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2136362974
- Cited by
- 55
- References
- 6
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.